ArticleCancers2021
Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A narrative review of the current state of circulating tumor cells in prostate cancer diagnostic.Hellenic urology · 2025Article
- Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.Cellular and molecular life sciences : CMLS · 2024Article
- Research progress on the multi-omics and survival status of circulating tumor cells.Clinical and experimental medicine · 2024Review
- How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy.Cancer metastasis reviews · 2023Review
- Review
- Role of myeloid-derived suppressor cells in tumor recurrence.Cancer metastasis reviews · 2023Review
- Article
- Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies.Cancers · 2022Article
- Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients.Cancers · 2022Review
- A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.Cancers · 2022Review
- Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Circulating tumor cells: biology and clinical significance.Signal transduction and targeted therapy · 2021Review
- The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer.Journal of clinical medicine · 2021Review
- The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Liquid biopsy-based biomarkers have advantages in monitoring the dynamics of metastatic castration-resistant prostate cancer (mCRPC), a bone-predominant metastatic disease. Previous studies have demonstrated associations between circulating tumor cells (CTCs) and clinical outcomes of mCRPC patients, but little is known about the prognostic value of CTC-clusters. In 227 longitudinally collected blood samples from 64 mCRPC patients, CTCs and CTC-clusters were enumerated using the CellSearch platform. The associations of CTC and CTC-cluster counts with progression-free survival (PFS) and overall survival (OS), individually and jointly, were evaluated by Cox models. CTCs and CTC-clusters were detected in 24 (37.5%) and 8 (12.5%) of 64 baseline samples, and in 119 (52.4%) and 27 (11.9%) of 227 longitudinal samples, respectively. CTC counts were associated with both PFS and OS, but CTC-clusters were only independently associated with an increased risk of death. Among patients with unfavorable CTCs (≥5), the presence of CTC-clusters signified a worse survival (log-rank
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.